Renal Function Is Associated with Changes in Bone Mineral Density in Postmenopausal Osteoporotic Women Treated with Denosumab: Data From a Retrospective Cohort Study
Authors:
- Antonino CatalanoAntonino Catalano
- Cecilia OliveriCOCecilia Oliveri
- Giuseppe NataleGNGiuseppe Natale
- Rita Maria AgostinoRARita Maria Agostino
- Giovanni SquadritoGSGiovanni Squadrito
- Agostino GaudioAgostino Gaudio
- Guido GembilloGuido Gembillo
- Djordje MarinaDMDjordje Marina
- Valeria CernaroVCValeria Cernaro
- Elisa LonghitanoELElisa Longhitano
- Giorgio BasileGiorgio Basile
- Nunziata MorabitoNMNunziata Morabito
Open Access
- 19 October 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (20) , 6239
Abstract
Background/Objectives: Renal function influences bone metabolism, as kidney failure can increase the risk of fractures. Denosumab is an approved osteoporosis treatment, but its efficacy in relation to renal function has not yet been studied in real-life scenarios. This study aimed to investigate the denosumab-induced change in bone mineral density (BMD) according to kidney function. Methods: A retrospective analysis was conducted at the outpatient clinic in postmenopausal women receiving denosumab (60 mg subcutaneously administered every 6 months). The glomerular filtration rate (eGFR) was measured by the 2021 CKD-EPI equation and patients were stratified for eGFR categories. BMD was measured by dual-energy X-ray absorptiometry. Results: 128 women (mean age 70.3 ± 9.4 years) were recruited. The mean denosumab treatment duration was 3.9 ± 1.4 years and all the participants had improved BMD values. In stepwise multiple regression analysis—after controlling for age, BMI, and treatment duration—the eGFR value (ß = −0.11, SE 0.04, p = 0.01) was independently associated with the lumbar spine BMD change. The same association remained when the eGFR categories were considered (ß = 3.564, SE 1.29, p = 0.007). In addition, after controlling for BMI and the duration of denosumab treatment, age (ß = −0.7915, SE 0.37, p = 0.03) and eGFR (ß = −0.3257, SE 0.1567, p = 0.04) were found to be associated with femoral neck BMD change. The association remained when considering eGFR categories (ß = 8.7339, SE 4.29, p = 0.04). Conclusions: This retrospective study suggests that eGFR is associated with denosumab efficacy in postmenopausal women treated for osteoporosis.Keywords
This publication has 32 references indexed in Scilit:
- Treatment of osteoporosis with denosumab in patients with decreased kidney functionArchives of Osteoporosis, 2023
- Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post‐Fracture Treatment, and All‐Cause MortalityJournal of Bone and Mineral Research, 2023
- Phosphate intake, hyperphosphatemia, and kidney functionPflügers Archiv - European Journal of Physiology, 2022
- Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safetyArchives of Osteoporosis, 2021
- SCOPE 2021: a new scorecard for osteoporosis in EuropeArchives of Osteoporosis, 2021
- Denosumab Improves Glomerular Filtration Rate in Osteoporotic Patients With Normal Kidney Function by Lowering Serum PhosphorusJournal of Bone and Mineral Research, 2019
- Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis TherapyJBMR Plus, 2018
- Hypocalcemia: a sometimes overlooked cause of heart failure in the elderlyAging Clinical and Experimental Research, 2012
- European guidance for the diagnosis and management of osteoporosis in postmenopausal womenOsteoporosis International, 2008
- Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairmentOsteoporosis International, 2006